C4X Discovery Holdings PLC
LSE:C4XD

Watchlist Manager
C4X Discovery Holdings PLC Logo
C4X Discovery Holdings PLC
LSE:C4XD
Watchlist
Price: 12 GBX 27.32% Market Closed
Market Cap: 30.3m GBX
Have any thoughts about
C4X Discovery Holdings PLC?
Write Note

Operating Margin
C4X Discovery Holdings PLC

38.1%
Current
-227%
Average
2.4%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
38.1%
=
Operating Profit
9.4m
/
Revenue
24.7m

Operating Margin Across Competitors

Country UK
Market Cap 30.3m GBP
Operating Margin
38%
Country US
Market Cap 1.3T USD
Operating Margin
14%
Country US
Market Cap 196.3B USD
Operating Margin
17%
Country US
Market Cap 170.3B USD
Operating Margin
21%
Country KR
Market Cap 66.5T KRW
Operating Margin
31%
Country CH
Market Cap 37.6B CHF
Operating Margin
13%
Country US
Market Cap 38.5B USD
Operating Margin
25%
Country US
Market Cap 36.7B USD
Operating Margin
14%
Country US
Market Cap 26.4B USD
Operating Margin
28%
Country US
Market Cap 23B USD
Operating Margin
20%
Country US
Market Cap 22.3B USD
Operating Margin
8%
No Stocks Found

C4X Discovery Holdings PLC
Glance View

Market Cap
30.3m GBX
Industry
Life Sciences Tools & Services

C4X Discovery Holdings Plc engages in the development of new technologies to improve the drug discovery process for novel small molecule therapies. The firm operates by early commercial partnering or initiation of a its drug discovery program to develop a small molecule. The firm also works in collaboration with partners. The firm has a portfolio ranging from early stage-target to late-stage drug discovery program ready for out-licensing to partners. The Company’s portfolio of pre-clinical small molecule candidates includes Oral NRF2 activator, Oral MALT1 inhibitor, Oral α4β7 integrin inhibitor, Oral Orexin-1 Antagonist (C4X_3256/INDV-2000), Oral IL-17A Inhibitor. The company has developed activators of the NRF2 pathway for the treatment of a variety of inflammatory diseases including Inflammatory Bowel Disease (IBD), Sickle Cell Disease (SCD), Pulmonary Arterial Hypertension (PAH) and Chronic Obstructive Pulmonary Disorder (COPD).

C4XD Intrinsic Value
43.44 GBX
Undervaluation 72%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
38.1%
=
Operating Profit
9.4m
/
Revenue
24.7m
What is the Operating Margin of C4X Discovery Holdings PLC?

Based on C4X Discovery Holdings PLC's most recent financial statements, the company has Operating Margin of 38.1%.